IL27 and neoplasm: Therefore, it is possible that the addition of IL-27 alongside STAT3 inhibitors may serve to further enhance their efficacy, as inhibition of STAT3 could favor STAT1-dominant signaling, promoting the anti-tumor capacity of IL-27.